Last night, the inaugural Broermann Medical Innovation Award honored Dr. Carl June & Dr. Michel Sadelain for their pioneering work in CAR-T cell therapy.
At the Hessian State Chancellery in Wiesbaden, the award was presented by Hessian Minister Boris Rhein.
𧏠CRISPR breakthrough: Supercharging CAR T cells by knocking out RHOG & FAS! đ Precision immunotherapy just leveled up. đŹ #CARTcells #CancerResearch #Genomics https://emmecola.github.io/genomics-daily
Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!
Their work stands as a shining example of how research excellence can translate into real-world impact!
In MĂŒnchen und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs â und macht sich dabei ein ungeklĂ€rtes PhĂ€nomen von Krebszellen zunutze. @InsertCaffeine erklĂ€rt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
'A year ago, Caribou Biotherapeuticsâ CEO was telling Fierce Biotech that the companyâs natural killer (NK) cell therapy program was the âtip of the spearâ for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to goâalong with 12% of Caribouâs workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities
'Twenty-nine different Car-T treatments for autoimmune diseases, ranging from the muscle inflammation condition myositis to multiple sclerosis, are now being tested in clinical trials by drugmakers including Novartis and Bristol Myers Squibb'
#Immunology #Autoimmunity #CARTcells
https://www.ft.com/content/a974f4c1-bb8a-4a1b-9d88-a2cf14be5c6e
'These studies have helped to answer âsome of the questions that were precipitated by the FDA announcement,â Maus said. They still have not found definitive evidence that CAR-T therapy has directly caused new cancers, she said, and scientists continue to suspect that such an event would be extremely rare.'
#Immunology #Immunotherapy #CARTcells
https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss
'Even without exposure to antigens, some CARs increase proliferation and nutrient uptake in T cells. Using stable isotope tracers and mass spectrometry, we observed basal metabolic fluxes through glycolysis doubling and amino acid uptake overtaking anaplerosis in CAR-T cells harbouring a rituximab scFv, unlike other similar anti-CD20 scFvs.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s42255-024-01034-7
'However, the established use of viral vectors for genetic engineering of CAR immune cells is still subject to particular safety concerns and requires further improvements. 1 Consequently, non-viral methods for immune cell engineering are gaining increasing interest. In this context, transposon-based technologies represent a promising alternative engineering technology that enables safe genomic insertions of large cargo, such as multi-cistronic CAR-expression cassettes, using fast and cost-effective manufacturing processes '
#Immunology #Immunotherapy #CARTcells
https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(24)00325-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001624003253%3Fshowall%3Dtrue
" The insights derived from this analysis do not only support a CD19 CAR T cell-mediated reset of the memory B cell compartment, but also the parallel inhibition of the interferon signature
in #monocytes and #Tcells of #SLE patients"
https://insight.jci.org/articles/view/179433
Striking that this apparently works better in getting rid of certain memory #Bcells than anti-CD20 antibodies.
'Although T cell depletion was greatly enhanced by CD47 blockade in our studies, our data demonstrate that macrophage phagocytosis limits the persistence of adoptively transferred T cells even in the absence of CD47âSIRPα blockade'
#Immunotherapy #Immunology #CARTcells
https://www.nature.com/articles/s41586-024-07443-8#Sec10
'Our results reveal an increased sensitivity of low affinity CAR-T cells to PD-L1-mediated inhibition when compared to their high affinity counterparts by using in vitro models of tumor cell lines and supported lipid bilayers modified to display varying PD-L1 densities.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s41467-024-47799-z
'Although the information provided by the FDA was thin at the time, the agency told reporters that it had observed 20 cases in which immune-cell cancers known as lymphomas had developed in people treated with CAR T cells. Levine, who is a co-inventor of Kymriah, the first CAR-T-cell therapy to be approved, started jotting down questions. Who were these patients? How many were there? And what other drugs had they received before having CAR-T-cell therapy?'
Regular exercise for 30 minutes a day has been shown to significantly reduce the risk of developing cancer. It is important to prioritize physical activity to maintain overall health and well-being. #Exercise #CancerPrevention #HealthAwareness #cancerfax #cartcelltherapy #cartcells #carttherapy #ball #leukemia #lymphoma
"Plenge and colleagues are laying out a three-part plan to tackle autoimmune diseases of all types. Under this vision, âstep oneâ drugs â including many available small molecules and antibodies â would be used to control the inflammation that marks these disease. âStep twoâ drugs, exemplified by CAR Ts, could be used to reset the immune system by taking out the pathogenic immune cells that drive the inflammation. And âstep threeâ drugs could promote homeostasis and the repair of any lasting damage."
#Immunology #Autoimmunity #AutoimmuneDisease #Immunotherapy #CARTcells
https://www.nature.com/articles/d41573-024-00069-5
'In Brazil, the Oswaldo Cruz Foundation, a vaccine manufacturer and the largest biomedical research institute in Latin America, recently partnered with a US-based nonprofit called Caring Cross to help develop local CAR-T manufacturing capabilities. Caring Cross has developed a point-of-care manufacturing process able to generate CAR-T therapies for an even lower costâroughly $20,000 in materials and $10,000 in labor and facilities.'
#Immunology #Immunotherapy #CARTcells
https://www.technologyreview.com/2024/04/12/1091161/car-t-cancer-therapy-treatment-expense/
The art of war:
"Pulling from cancerâs playbook, Roybal and his colleagues incorporated 71 mutations, found in cancerous T cells, into CAR T cells. When they looked at how these perturbations affected T-cell function, one mutation stood out. The CAR T cells carrying an aberrant protein dubbed CARD11âPIK3R3 infiltrated well into tumours and had long-lasting cancer-killing activity."
#Immunology #immunotherapy #CARTcells
CAR T cells target senescent cells, improve healthspan in mice
https://www.news-medical.net/news/20240202/CAR-T-cells-target-senescent-cells-improve-healthspan-in-mice.aspx
'The present study illustrates great potentials of chimeric antigen receptor (CAR-T) cells targeting B cell maturation antigen in treating anti-signal recognition particle myopathy, with sustained depletion of autoantibodies and therapeutic efficacies beyond 18 mo.'
#immunotherapy #CARTcells
"The highly migratory phenotype is mediated by a paracrine pathway from a group of self-produced inflammatory cytokines that include IL5, TNFα, IFNÎł, and IL8. We exploit this finding to âlock-inâ a highly migratory phenotype by developing and expressing receptors, which we call velocity receptors"
#Immunology #Immunotherapy #Preprint #CARTcells
